Compare Amcor PLC (AMCR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amcor PLC vs Twist Bioscience Corp — how do they compare? Amcor PLC trades at $46.47 (market cap $21.92B), while Twist Bioscience Corp trades at $123.66 (market cap $7.72B). The key difference: Amcor PLC is far larger — about 2.8× Twist Bioscience Corp's market cap, and Amcor PLC pays a 5.49% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| AMCR | TWST | |
|---|---|---|
Market Cap | $21.92B | $7.72B |
Sector | Basic Materials | Health |
52-Week High | $50.58 | $124.88 |
52-Week Low | $36.69 | $24.16 |
Enterprise Value | $37.03B | $7.65B |
Dividend Yield | 5.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMCR trades at $47.11, down 1.57% today, near the consensus price target of $47.00. Recent quarters show consistent earnings beats, with Q4 2026 revenue up 26% year-over-year to $6.4 billion, driven by the Berry acquisition (PRNewsWire, Aug 12, 2026). Technical indicators signal a bullish trend, while valuation ratios like P/E of 38.07 appear elevated relative to historical margins. The company maintains a solid dividend, with a $0.65 payment scheduled for June 2026.
Outlook is cautiously optimistic given strong revenue growth and analyst buy ratings (64% consensus), but risks include high debt levels and margin pressure, with net income margin declining to 3.06% in 2025. Investors should weigh acquisition benefits against integration challenges and cyclical demand headwinds in packaging markets.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amcor PLC
Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.
Read more on AMCR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
